Trial Profile
Once Daily Intravenous Busulfex as Part of Reduced-toxicity Conditioning for Patients With Relapsed/Refractory Hodgkin's and Non-Hodgkin's Lymphomas Undergoing Allogeneic Hematopoietic Progenitor Cell Transplantation - A Multicenter Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Graft-versus-host disease; Hodgkin's disease; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 24 Apr 2023 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 30 Jun 2020 to 30 Jun 2022.
- 06 Apr 2021 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2021.